TITLE

Intradermal vaccine licensed for 2011-12 flu season

AUTHOR(S)
Traynor, Kate
PUB. DATE
July 2011
SOURCE
American Journal of Health-System Pharmacy;7/15/2011, Vol. 68 Issue 14, p1288
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article offers details related to Sanofi Pasteur's influenza flu vaccine product, Fluzone intradermal which is the the first vaccine approved by FDA for intradermal administration in people 18–64 years of age. Comments pertaining to the same are cited by professor Stephan L. Foster along with a emphasizing on updating the American Pharmacists Association's (APhA's) immunization certification program. Also highlighted is its labeling information which includes postinjection reactions.
ACCESSION #
63195803

 

Related Articles

  • New twists in flu vaccinations. JONES, TEDDY // Farmer-Stockman;Dec2011, Vol. 101 Issue 12, p56 

    The article offers information about flu vaccination in terms on the reasons to vaccinate, vulnerability of influenza to other infections, and the availability of an intradermal injection for people aged 18 to 64 years old.

  • FDA approves new intradermal vaccine for influenza.  // Infectious Disease News;Jun2011, Vol. 24 Issue 6, p34 

    The article reports on the approval of the first intradermal influenza virus vaccine by the U.S. Food and Drug Administration (FDA).

  • Immunogenicity and Safety of Intradermal Influenza Vaccination in Healthy Older Adults. Chi, Ru-Chien; Rock, Michael T.; Neuzil, Kathleen M. // Clinical Infectious Diseases;5/15/2010, Vol. 50 Issue 10, p1331 

    Background. Influenza vaccine immunogenicity is suboptimal in older persons. Intradermal (ID) vaccination may be a promising alternative to intramuscular (IM) vaccination.Methods. This randomized trial compared the immunogenicity of 60% dose ID influenza vaccination to standard IM vaccination of...

  • Immunogenicity and Safety of Intradermal Influenza Vaccination in Healthy Older Adults. Chi, Ru-Chien; Rock, Michael T.; Neuzil, Kathleen M. // Clinical Infectious Diseases;5/15/2010, Vol. 50 Issue 10, p1331 

    Background. Influenza vaccine immunogenicity is suboptimal in older persons. Intradermal (ID) vaccination may be a promising alternative to intramuscular (IM) vaccination.Methods. This randomized trial compared the immunogenicity of 60% dose ID influenza vaccination to standard IM vaccination of...

  • An alternative route to influenza immunization. Chambers, Christopher V.; Russell, John J. // Patient Care;Feb2005, Vol. 39 Issue 2, p72 

    Discusses research being done on serum antibody responses after intradermal vaccination against influenza. Reference to a study by R. B. Belshe and colleagues, published in the 2004 issue of the "New England Journal of Medicine"; Analysis of the immunogenicity of influenza vaccine; Findings of...

  • Intanza 15 μg Intradermal Seasonal Influenza Vaccine. Duggan, Sean T.; Plosker, Greg L. // Drugs & Aging;2010, Vol. 27 Issue 7, p597 

    Intradermal seasonal influenza vaccine delivered by a microneedle injection system (Intanza®) contains inactivated split virion antigens from influenza type A (H1N1 and H3N2) and B strains as recommended annually by the WHO and the EU for the prevention of seasonal influenza. In randomized,...

  • Intradermal influenza vaccine. Tanzi, Maria G. // Pharmacy Today;Aug2011, Vol. 17 Issue 8, p52 

    The article reports on the approval of an intradermal formulation of the vaccine Fluzone Intradermal by the U.S. Food and Drug Administration (FDA) for active immunization of adults aged 18 to 64 years against influenza disease caused by virus subtypes A and B. The vaccine will include an...

  • Long-term immunogenicity of the influenza vaccine at reduced intradermal and full intramuscular doses among healthy young adults. Joon Young Song; Hee Jin Cheong; Ji Yun Noh; Tae Un Yang; Yu Bin Seo; Kyung-Wook Hong; In Seon Kim; Won Suk Choi; Woo Joo Kim // Clinical & Experimental Vaccine Research;Jul2013, Vol. 2 Issue 2, p115 

    Purpose: To prepare for vaccine shortages under an influenza pandemic, several antigen-sparing strategies have been investigated. This study was aimed to evaluate the immunogenicity of influenza vaccine at reduced intradermal and full intramuscular dose. Materials and Methods: We compared the...

  • No systemic reactions to influenza vaccination in egg-sensitized tertiary-care pediatric patients. Upton, Julia Elizabeth Mainwaring; Hummel, David Brian; Kasprzak, Anna; Atkinson, Adelle Roberta // Allergy, Asthma & Clinical Immunology;2012, Vol. 8 Issue 1, p1 

    Background: There are numerous, disparate guidelines for influenza vaccination in egg-allergic patients. We aimed to describe the outcome of selectively applied guidelines, based on risk-stratification, to our high risk, egg-allergic, tertiary-care pediatric population. Methods: Egg allergy was...

  • CPT® 2012 Includes Intradermal Flu Vaccine Option With 90654.  // Family Practice Coding Alert;Dec2011, Vol. 13 Issue 12, p81 

    The article reports on the revisions of the Current Procedural Terminology (CPT) 2012 including the intradermal flu vaccine option with 90654 in the U.S. The code covers influenza virus vaccine, preservative-free, and split virus for intradermal use. It represents an intradermal injection, while...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics